|Articles|August 1, 2019
- Pharmaceutical Executive-08-01-2019
- Volume 39
- Issue 8
Pharmaceutical Executive, August 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive August 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 7 years ago
A Look Back & Forward on Innovationabout 7 years ago
Routes to Exclusivity in Cell-Based Therapy Developmentabout 7 years ago
Gene Therapy: Managing the Clinical Trial Minefieldsabout 7 years ago
The Call to Cure: Geoff MacKay, AVROBIOabout 7 years ago
Four Takeaways from the Zolgensma Pricing Stormabout 7 years ago
FDA Faces ‘Explosion’ in Growth of Gene Therapiesabout 7 years ago
Mapping Out the Future of Cell and Gene Therapyabout 7 years ago
High-Stakes Manufacturing: Mitigating the Risksabout 7 years ago
Gene Therapy: How ‘Advanced’ is Europe?about 7 years ago
Luxturna: A Vision for Curative Therapy AccessAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
2
FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer
3
The Retailization of Medicare Advantage: What Costco’s Entry Means for Pharma
4
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
5